The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
The companies will use their respective technologies to identify inhibitors of cancer-associated gene targets and optimize their use as therapeutics.
The drugmaker hopes to submit this data as part of a new drug application with the FDA later this year.
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
Funded projects will look at the combination of imaging and liquid biopsies for monitoring cancer patient responses and the emergence of treatment resistance.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.
The deal with AstraZeneca follows a licensing agreement signed earlier this year with Memorial Sloan Kettering Cancer Center also covering radionuclide PARP inhibitor IP.
The study failed to show Opdivo plus chemoradiation significantly improves PFS compared to standard of care in MGMT-methylated glioblastoma.
Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.
The researchers aimed to develop a test that could help clinicians determine whether a patient would respond to therapy, before the onset of treatment.